Drug-drug interactions of ritonavir-boosted SARS-CoV-2 protease inhibitors in solid organ transplant recipients: experience from the initial use of lopinavir-ritonavir

Letter Surgery

Effect of nirmatrelvir/ritonavir on calcineurin inhibitor levels: Early experience in four SARS-CoV-2 infected kidney transplant recipients

Aileen X. Wang et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

Article Medicine, General & Internal

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Jennifer Hammond et al.

Summary: In high-risk, unvaccinated adults, treatment of Covid-19 with nirmatrelvir plus ritonavir can significantly reduce the risk of hospitalization and death, with good safety profile.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Surgery

Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients

David M. Salerno et al.

Summary: The use of Nirmatrelvir/ritonavir (NR) in solid organ transplant recipients (SOTRs) with mild COVID-19 has not been described yet. The objective of this study was to evaluate outcomes among SOTRs and describe the drug-drug interaction of NR. The results show that the clinically significant interaction between NR and immunosuppressive agents can be reasonably managed with a standardized dosing protocol.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

Add to Collection

Article Immunology

Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report

Marios Prikis et al.

Summary: The COVID-19 pandemic has impacted communities and health systems significantly, and new antiviral medications have not been thoroughly tested. Drug interactions may affect the treatment outcomes of organ transplant recipients, emphasizing the importance of monitoring for adverse effects.

TRANSPLANTATION PROCEEDINGS (2022)

Add to Collection

Article Surgery